Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
876 results:
1. Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
Kim SM; Park N; Park HB; Lee J; Chun C; Kim KH; Choi JS; Kim HJ; Choi S; Lee JH
PLoS One; 2024; 19(5):e0303433. PubMed ID: 38743676
[TBL] [Abstract] [Full Text] [Related]
2. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract] [Full Text] [Related]
3. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy.
Blaya-Cánovas JL; Griñán-Lisón C; Blancas I; Marchal JA; Ramírez-Tortosa C; López-Tejada A; Benabdellah K; Cortijo-Gutiérrez M; Cano-Cortés MV; Graván P; Navarro-Marchal SA; Gómez-Morales J; Delgado-Almenta V; Calahorra J; Agudo-Lera M; Sagarzazu A; Rodríguez-González CJ; Gallart-Aragón T; Eich C; Sánchez-Martín RM; Granados-Principal S
Mol Cancer; 2024 May; 23(1):83. PubMed ID: 38730475
[TBL] [Abstract] [Full Text] [Related]
4. [Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer].
Liu B; Yuan Y; Li F; Li JB; Bian L; Wang T; Zhang SH; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1507-1513. PubMed ID: 38706058
[No Abstract] [Full Text] [Related]
5. PD-1/pd-l1 pathway: Current research in breast cancer.
Syamsu SA; Faruk M; Smaradania N; Sampepajung E; Pranoto AS; Irsandy F; Tammasse IFU
Breast Dis; 2024; 43(1):79-92. PubMed ID: 38701137
[TBL] [Abstract] [Full Text] [Related]
6. Epithelial Expressed b7-h4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative breast cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract] [Full Text] [Related]
8. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/pd-l1 signaling.
Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
[TBL] [Abstract] [Full Text] [Related]
9. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer.
Liu X; Wang W; Chen B; Wang S
Aging (Albany NY); 2024 Apr; 16(8):7188-7216. PubMed ID: 38643462
[TBL] [Abstract] [Full Text] [Related]
10. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract] [Full Text] [Related]
11. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular pd-l1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract] [Full Text] [Related]
12. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
13. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract] [Full Text] [Related]
14. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression.
Tao J; Shen L; Zhuang M; Zhai C; Zeng H; Mao Y; Liu X
FASEB J; 2024 Apr; 38(7):e23582. PubMed ID: 38568853
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S; Kraxner A; Cheng WY; Ou Yang TH; Flores M; Theiss N; Tsao TS; Andersson E; Harring SV; Bröske AE; Ceppi M; Teichgräber V; Charo J
Front Immunol; 2024; 15():1352615. PubMed ID: 38558814
[TBL] [Abstract] [Full Text] [Related]
17. Formononetin Restrains Tumorigenesis of breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of pd-l1.
Liu H; Wang Z; Liu Z
Discov Med; 2024 Mar; 36(182):613-620. PubMed ID: 38531802
[TBL] [Abstract] [Full Text] [Related]
18. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Zhu Y; Banerjee A; Xie P; Ivanov AA; Uddin A; Jiao Q; Chi JJ; Zeng L; Lee JY; Xue Y; Lu X; Cristofanilli M; Gradishar WJ; Henry CJ; Gillespie TW; Bhave MA; Kalinsky K; Fu H; Bahar I; Zhang B; Wan Y
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38530357
[TBL] [Abstract] [Full Text] [Related]
19. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract] [Full Text] [Related]
20. Assessing the relationship between tumor-infiltrating lymphocytes and pd-l1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract] [Full Text] [Related]
[Next]
